Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04385290
Previous Study | Return to List | Next Study

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04385290
Recruitment Status : Recruiting
First Posted : May 12, 2020
Last Update Posted : September 30, 2020
Sponsor:
Collaborators:
Novartis Pharmaceuticals
Pfizer
Information provided by (Responsible Party):
Technische Universität Dresden

Tracking Information
First Submitted Date  ICMJE May 8, 2020
First Posted Date  ICMJE May 12, 2020
Last Update Posted Date September 30, 2020
Actual Study Start Date  ICMJE September 4, 2020
Estimated Primary Completion Date May 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 8, 2020)
  • Maximum tolerated dose (MTD) of midostaurin and GO combination [ Time Frame: treatment day 8 until day 42 at the latest ]
    as measured by the number of dose limiting toxicities related to midostaurin or GO exposure.
  • Event Free Survival (EFS) [ Time Frame: up to 5 years from enrolment ]
    Time interval from date of randomization until either primary treatment failure or relapse or death, whichever occurs first.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 12, 2020)
  • CR/CRi rate [ Time Frame: after induction treatment, approx. 2 months ]
    CR/CRi rate is defined as the proportion of patients, who achieved a morphologic complete remission or a complete remission with incomplete hematologic recovery (CR or CRi) during study participation.
  • Depth of remission [ Time Frame: after induction treatment, approx. 2 months ]
    Quantification of measurable residual disease (MRD)
  • Duration of remission [ Time Frame: up to 5 years from enrolment ]
    Duration of remission is defined as time interval from date of CR/CRi until morphologic relapse.
  • Cumulative incidence of relapse [ Time Frame: up to 5 years from enrolment ]
    Cumulative incidence of relapse is defined as the time interval from date of first CR/CRi until relapse.
  • Relapse-free survival [ Time Frame: up to 5 years from enrolment ]
    Relapse-free survival is defined as the time interval from date of first CR/CRi until either morphologic relapse or death in remission.
  • Overall survival [ Time Frame: up to 5 years from enrolment ]
    Overall survival is defined as time interval from date of randomization until death from any cause.
  • Early mortality rate [ Time Frame: 30 and 60 days after commencement of therapy ]
    Early mortality is defined as death from any reason within 30 days and 60 days from start of induction.
  • Incidence and severity of adverse events (tolerability) [ Time Frame: until 2 months after commencement of therapy; up to app. 1,5 years after commencement of therapy ]
    Number and grade of adverse events assessed by CTCAE v5.0
  • CD33 expression of AML blasts [ Time Frame: after 18 months of study treatment ]
    Proportion of AML blasts positive for CD33 antigen
  • Proportion of allogeneic stem cell transplantation [ Time Frame: up to 5 years from enrolment ]
    Number of patients with allogeneic stem cell transplantations following response to induction.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 8, 2020)
  • CR/CRi rate [ Time Frame: after induction treatment, approx. 2 months ]
    CR/CRi rate is defined as the proportion of patients, who achieved a morphologic complete remission or a complete remission with incomplete hematologic recovery (CR or CRi) during study participation.
  • Depth of remission [ Time Frame: after induction treatment, approx. 2 months ]
    Quantification of measurable residual disease (MRD) by PCR-based RUNX1-RUNX1T1 or CBFB-MYH11 measurements and by multicolor flow cytometry
  • Duration of remission [ Time Frame: up to 5 years from enrolment ]
    Duration of remission is defined as time interval from date of CR/CRi until morphologic relapse.
  • Cumulative incidence of relapse [ Time Frame: up to 5 years from enrolment ]
    Cumulative incidence of relapse is defined as the time interval from date of first CR/CRi until relapse.
  • Relapse-free survival [ Time Frame: up to 5 years from enrolment ]
    Relapse-free survival is defined as the time interval from date of first CR/CRi until either morphologic relapse or death in remission.
  • Overall survival [ Time Frame: up to 5 years from enrolment ]
    Overall survival is defined as time interval from date of randomization until death from any cause.
  • Early mortality rate [ Time Frame: 30 and 60 days after commencement of therapy ]
    Early mortality is defined as death from any reason within 30 days and 60 days from start of induction.
  • Incidence and severity of adverse events (tolerability) [ Time Frame: until 2 months after commencement of therapy; up to app. 1,5 years after commencement of therapy ]
    Number and grade of adverse events assessed by CTCAE v5.0
  • CD33 expression of AML blasts [ Time Frame: after 18 months of study treatment ]
    Proportion of AML blasts positive for CD33 antigen
  • Proportion of allogeneic stem cell transplantation [ Time Frame: up to 5 years from enrolment ]
    Number of patients with allogeneic stem cell transplantations following response to induction.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Official Title  ICMJE MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Brief Summary This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine Kinase 3 (FLT3) mutation.
Detailed Description

Acute myeloid leukemia is a malignancy that is still fatal for the majority of patients. Besides age, the genetic configuration of AML blasts is one of the strongest prognostic factors. Patients with mutations in the core-binding factor (CBF) genes have the best prognosis, however a considerable proportion of 35-60% will eventually relapse. Mutation and overexpression of receptor tyrosinkinases (RTK) have been proposed as main reasons for relapse development or chemoresistance in CBF AMLs. RTKs like stem cell factor receptor (c-KIT) and FLT3 are of high clinical relevance as they mediate proliferation and differentiation of hematopoietic stem cells. There is evidence that c-Kit mutations and high levels of c-KIT in CBF-AML have adverse effects on survival endpoints indicating c-KIT as potential therapeutic target in this special AML population. Midostaurin can be considered a potent c-KIT inhibitor besides having multi-kinase inhibitory activity for several other kinases of documented or potential pathogenetic relevance for AML, most importantly mutated FLT3. The kinase inhibition ultimately leads to inhibition of proliferation, cell cycle arrest, and apoptosis. Previous studies with other c-KIT inhibitors such as dasatinib showed promising results with respect to survival end points in newly diagnosed CBF AML patients. Midostaurin is considered a more potent c-KIT inhibitor than dasatinib and may be able to potentiate the inhibitory effect on leukemic cell growth.

Another important therapeutical target in CBF AML is the sialic acid-binding immunoglobulin-like lectin (CD33) which is expressed on the majority of AML blasts. Gemtuzumab Ozogamicin (GO) is a therapeutic CD33 antibody linked to a strong cytostatic drug (calicheamicin) which causes apoptosis of cancer cells upon internalization. For the combination of GO and standard intensive chemotherapy, metaanalyses of randomized trials have shown that i) a low-dose fractionated administration results in the best tolerability, and ii) among AML subgroups, patients with CBF AML have the greatest benefit from GO in addition to standard therapy. Subgroup analyses within the ALFA-0701 (A Randomized Study of Gemtuzumab Ozogamicin With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia Aged of 50-70 Years Old) trial population showing beneficial effects of GO on overall survival, relapse-free survival and event-free survival in patients positive for FLT3 mutation as compared to those negative for FLT3 mutation. Subgroup analyses of the GO registration trial ALFA-0701 showed a significant clinical benefit of the patients displaying a mutation in the FLT3 gene compared to those without this mutation. In Addition, CBF AML patients with FLT3 mutations expressed particularly high levels of CD33 antigen and that CD33 antigen levels were positively correlated to the improved survival after GO treatment. Furthermore, recently published data of two paediatric populations with internal tandem mutation in the FLT3 gene showed reduced relapse rates in GO recipients compared to the control group only receiving standard chemotherapy. These results suggest that GO is a particularly beneficiary agent in FLT3 mutated patients who would currently receive midostaurin in addition to intensive chemotherapy as a standard of care. Hence, from a clinical point of view there is an unambiguous rationale supporting the combination of midostaurin and GO for treatment of AML in the two cytogenetic subgroups: CBF AML and FLT3 mutated AML.

GO has become the new treatment standard for patients with CBF AML. The hypothesized positive effect of midostaurin is likely but randomized proof is laking.

Midostaurin has become the new treatment standard for AML patients with mutations in the FLT3 gene. The positive effect of GO is shown in a post-hoc subgroup analysis of the ALFA-0701 trial, but prospective randomized proof is lacking.

Therefore, the proposed trial intends i) to explore and establish the safe combination of GO plus midostaurin (MODULE) and ii) to evaluate the effect of midostaurin versus placebo added to standard AML chemotherapy plus GO in CBF AML (MAGNOLIA) and iii) to evaluate the effect of GO versus no GO added to standard AML chemotherapy plus midostaurin in FLT3 mutated AML (MAGMA).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The phase I dose escalation trial (MODULE) will be conducted according to the 3+3 design.

The phase II trial in CBF AML (MAGNOLIA) will be conducted in a double-blinded and randomized manner.

The phase II trial in FLT3 mutated AML (MAGMA) will be conducted in a open label and randomized manner.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Since the trial part MAGNOLIA is designed to be double-blinded, patients, investigators, site personnel, study team members, and anyone involved in the study conduct will remain blinded to the identity of the study drug midostaurin / placebo from the time of randomization until database lock for the primary endpoint analysis.
Primary Purpose: Treatment
Condition  ICMJE Acute Myeloid Leukemia
Intervention  ICMJE
  • Drug: MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO

    Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level

    GO (IMP) induction: 3 mg/m^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level

    Daunorubicin (DNR, non-IMP) induction: 60 mg/m^2/day i.v., days 1 to 3

    Cytarabine (AraC, non-IMP) induction: 200 mg/m^2/day cont. infusion, days 1 to 7

    Other Names:
    • Rydapt
    • Mylotarg
  • Drug: MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO

    Midostaurin (IMP):

    RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;

    GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only

    Daunorubicin (DNR, non-IMP):

    60 mg/m^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders

    Cytarabine (AraC, non-IMP):

    200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Other Names:
    • Rydapt
    • Mylotarg
  • Drug: MAGNOLIA-trial: Placebo associated with conventional chemotherapy (AraC+DNR)+GO

    Placebo:

    peroral, days 8 to 21, 1-2 induction cycles; peroral BID, days 8 to 21, 3 consolidation cycles; peroral BID, days 1 to 28, 12 maintenance cycles;

    GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only

    Daunorubicin (DNR, non-IMP):

    60 mg/m^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders

    Cytarabine (AraC, non-IMP):

    200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Other Name: Mylotarg
  • Drug: MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin

    Midostaurin (IMP):

    RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;

    GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only

    Daunorubicin (DNR, non-IMP):

    60 mg/m^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders

    Cytarabine (AraC, non-IMP):

    200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Other Names:
    • Mylotarg
    • Rydapt
  • Drug: MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin

    Midostaurin (IMP):

    RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles

    Daunorubicin (DNR, non-IMP):

    60 mg/m^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders

    Cytarabine (AraC, non-IMP):

    200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles

    Other Name: Rydapt
Study Arms  ICMJE
  • Experimental: MODULE trial: dose escalation
    Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m^2 i.v. on days 1 to 3).
    Intervention: Drug: MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO
  • Experimental: MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin
    Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
    Intervention: Drug: MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO
  • Placebo Comparator: MAGNOLIA-trial: conventional chemotherapy+GO and placebo
    Phase II (Trial part MAGNOLIA): placebo is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
    Intervention: Drug: MAGNOLIA-trial: Placebo associated with conventional chemotherapy (AraC+DNR)+GO
  • Experimental: MAGMA-trial: conventional chemotherapy+midostaurin and GO
    Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML
    Intervention: Drug: MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin
  • Active Comparator: MAGMA-trial: conventional chemotherapy+midostaurin
    Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v plus midostaurin). No additional GO is given.
    Intervention: Drug: MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 8, 2020)
214
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 2028
Estimated Primary Completion Date May 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent
  • Newly diagnosed AML according to the criteria of the World Health Organisation plus the following molecular or cytogenetic specifications:

    • Phase I Trial - MODULE:

      • t(8;21)/RUNX1-RUNX1T1 or
      • inv(16) or t(16;16)/CBFB-MYH11 or
      • FLT3-ITD or
      • FLT3-tyrosine kinase domain (FLT3-TKD)
    • Phase II Trial - MAGNOLIA

      • t(8;21)/RUNX1-RUNX1T1 or
      • inv(16) or t(16;16)/CBFB-MYH11
      • FLT3 wild-type
    • Phase II Trial - MAGMA

      • FLT3-ITD or
      • FLT3-TKD
  • Male and female patients with age

    • 18 - ≤ 75 years in Phase I Trial - MODULE or Phase II Trial - MAGNOLIA
    • 18 - ≤ 60 years in Phase II Trial - MAGMA
  • Eastern Cooperative Oncology Group (ECOG) Score of 0-2
  • Life expectancy > 14 days
  • Adequate hepatic and renal function

    • alanine aminotransferase / aspartate transaminase ≤ 2.5 x ULN
    • Bilirubin < 2 x upper limits of normal
    • Creatinine < 1.5 x upper limits of normal or Creatinine clearance > 40 ml/min
  • White blood cell count < 30 × 10^9/L. Note: Hydroxyurea is permitted to meet this criterion.

Exclusion Criteria (all study parts):

  • Previous antineoplastic treatment for AML other than hydroxyurea
  • Previous treatment with anthracyclines
  • central nervous system involvement
  • Isolated extramedullary AML
  • Uncontrolled infection
  • AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g., azacytidine or decitabine)
  • Any investigational agent within 30 days or 5 half-lives, whichever is greater, prior to day 1. An investigational agent is defined as an agent with no approved medical use in adults or in pediatric patients
  • Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib)
  • Strong CYP3A4/5 enzyme inducing drugs unless they can be discontinued or replaced prior to enrollment
  • Any other known disease or concurrent severe and/or uncontrolled medical condition (e.g., cardiovascular disease including congestive heart failure or active uncontrolled infection) that could compromise participation in the study
  • Impairment of gastrointestinal (GI) function or GI disease that might alter significantly the absorption of midostaurin
  • Confirmed diagnosis of HIV infection or active viral hepatitis
  • Cardiovascular abnormalities, including any of the following:

    • History of myocardial infarction, angina pectoris, Coronary Artery Bypass Grafting within 6 months prior to starting study treatment
    • Clinically uncontrolled cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II and third degree atrioventricular block)
    • Uncontrolled congestive heart failure
    • Left ventricular ejection fraction of < 50%
    • Poorly controlled arterial hypertension
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they fulfill at least one of the following criteria:

    • Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum follicule stimulating hormone > 40 U/ml)
    • Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy
    • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days before the first dose of study drug
    • Continuous and correct application of a contraception method with a Pearl Index of < 1% (e.g. implants, depots, oral contraceptives, intrauterine device) from initial study drug administration until at least 7 months after the last dose of gemtuzumab ozogamicin and at least 4 months after the last dose of midostaurin, whichever period is longer. A hormonal contraception method must always be combined with a barrier method (e.g. condom)
    • Sexual abstinence
    • Vasectomy of the sexual partner
  • Sexually active males unless they use a condom during intercourse while taking the drug during treatment, and for at least 4 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via semen
  • Unwillingness or inability to comply with the protocol
  • Known hypersensitivity to midostaurin, GO, cytarabine or daunorubicin or to any of the excipients of midostaurin/placebo, GO, cytarabine or daunorubicin.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Christoph Röllig, Prof. Dr. +49 351 458 ext 3775 MOSAIC@ukdd.de
Contact: Manja Reimann, Dr. +49 351 458 ext 3091 MOSAIC@ukdd.de
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04385290
Other Study ID Numbers  ICMJE TUD-MOSAIC-075
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Technische Universität Dresden
Study Sponsor  ICMJE Technische Universität Dresden
Collaborators  ICMJE
  • Novartis Pharmaceuticals
  • Pfizer
Investigators  ICMJE
Principal Investigator: Christoph Röllig, Prof. Dr. Technische Universität Dresden, Medical Faculty Carl Gustav Carus
PRS Account Technische Universität Dresden
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP